<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092017000200055</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Riesgo de desarrollo de Candida no albicans en pacientes en terapia intensiva con uso previo de fluconazol]]></article-title>
<article-title xml:lang="en"><![CDATA[Risk of developing Candida not albicans in patients in intensive care unit with previous use of fluconazole]]></article-title>
<article-title xml:lang="pt"><![CDATA[Risco de desenvolvimento de Candida não-albicans em pacientes nos cuidados intensivos com uso prévio de fluconazol]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pedraza Montenegro]]></surname>
<given-names><![CDATA[Axel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Olvera Guzmán]]></surname>
<given-names><![CDATA[Claudia I]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguirre Sánchez]]></surname>
<given-names><![CDATA[Janet Silvia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Camarena Alejo]]></surname>
<given-names><![CDATA[Gilberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Franco Granillo]]></surname>
<given-names><![CDATA[Juvenal]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Médico ABC Departamento de Medicina Crítica «Dr. Mario Shapiro» ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<volume>31</volume>
<numero>2</numero>
<fpage>55</fpage>
<lpage>59</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092017000200055&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092017000200055&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092017000200055&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  La candidemia es una entidad clínica que se ha incrementado en pacientes en terapia intensiva, el inmuncompromiso y la invasión múltiple en estos pacientes los hace sujetos lábiles a la diseminación por hongos y por ende al incremento de mortalidad. El uso de puntajes para estimar el riesgo de desarrollar candidemia ha permitido iniciar de forma profiláctica antifúngicos, en su mayoría de tipo azoles; sin embargo, el crecimiento de Candida no albicans se ha incrementado, lo que genera incertidumbre acerca del beneficio que pueden tener estas medidas iniciadas en forma temprana en la mortalidad.  Objetivos:  Determinar si los pacientes que ingresan a la unidad de terapia intensiva que han recibido de forma profiláctica algún antifúngico del tipo azol tienen mayor incidencia en el desarrollo de especias de Candida no albicans.  Métodos:  Estudio retrospectivo, longitudinal y analítico. Pacientes mayores de 18 años que ingresan a la unidad de terapia intensiva con diagnóstico de sepsis. Se determinó qué pacientes han recibido de forma profiláctica azoles y de éstos quienes han desarrollado especies de Candida albicans y no albicans.  Análisis estadístico:  Se realizó análisis estadístico mediante T de Student para comparación de grupo y &#967;2 para variables categóricas. Los resultados se expresan en promedio, ±, desviación estándar y porcentajes. Se considera estadísticamente significativo si p &#8804; 0.05, análisis con uso de sistema de estadística SPSS Statistics 21.  Resultados:  Veinticinco pacientes en periodo de dos años, edad 72 ± 13 años (45-92), 15 hombres (60%), sepsis abdominal 56% (n = 14), APACHE II 14 ± 5 (5-29) y SOFA 6 ± 3. Cultivos sin crecimiento en 16 pacientes (64%), Candida albicans 4 (16%) y no albicans en 5 (20%).  Conclusiones:  La incidencia de Candida no albicans en pacientes que reciben profilaxis con fluconazol es baja, sin incremento en mortalidad, por lo que consideramos que el uso de fluconazol como manejo profiláctico sigue siendo una medida adecuada en este grupo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Candidemia is a clinical entity increasing in patients in intensive care unit, the inmuncompromised and multiple invasion makes them subject of fungal dissemination and increase in mortality. Use of scores to estimate the risk of developing candidemia has allowed start prophylactic antifungal azoles; however, the development of Candida albicans has not increased, generating uncertainty about the benefit that can have these measures initiated in early mortality.  Objectives:  To determine whether patients who received prophylactic any antifungal azole has impact on the development of Candida non-albicans in patients admitted to the intensive care unit.  Methods:  A retrospective, longitudinal, analytical study. Patients over 18 years enter the intensive care unit with sepsis. Determined that patients received prophylactic azoles and those who have developed Candida albicans and non-albicans.  Statistical analysis: Statistical analysis was performed using Student T for comparison group and &#967; 2 for categorical variables. The results are expressed in average, ±, standard deviation and percentage. It is considered statistically significant if p &#8804; 0.05, analysis using statistical system SPSS Statistics 21.  Results:  25 patients, 2-year period, age 72 ± 13 years (45-92), 15 men (60%), abdominal sepsis 56% (n = 14), APACHE II 14 ± 5 (5-29) and SOFA 6 ± 3. Culture without growth in 16 patients (64%), Candida albicans 4 (16%) and non albicans in 5 (20%).  Conclusions:  The incidence of Candida albicans in patients not receiving prophylaxis with fluconazole is low, with no increase in mortality, and we believe that the use of fluconazole as prophylactic management remains an appropriate measure in this group.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  candidemia é uma entidade clínica que tem aumentado em pacientes em cuidados intensivos, o inmuncompromiso e invasão múltipla nestes pacientes torna assunto disseminação do fungo lábil e portanto, a um aumento da mortalidade. Usando pontuação para estimar o risco de desenvolver candidemia permitiu iniciar antifúngicos profiláticos, em tipo principalmente azóis; no entanto, o crescimento de Candida albicans nenhuma aumentou, criando incerteza sobre o benefício pode ter essas medidas iniciadas na mortalidade precoce.  Objetivos:  Para determinar se os doentes que entra na unidade terapia que eles receberam intenso profilaticamente qualquer azole tipo antifúngico eles têm uma maior incidência no desenvolvimento de não-albicans especiarias Candida. Um estudo retrospectivo, longitudinal e analítica. pacientes idosos 18 entrar na unidade de cuidados intensivos com diagnóstico de sepse. Determinou-se que os pacientes receberam azóis e profiláticos daqueles que desenvolveram espécies de Candida albicans e não-albicans.  Análise estatística: A análise estatística foi realizada utilizando t de Student para comparação de grupo e &#967;2 para variáveis &#8203;&#8203;categóricas. Os resultados são. Eles expressos em média ± desvio padrão e a percentagem média. Considera-se estatisticamente se p &#8804; 0,05 significativa, a análise estatística utilizando o sistema SPSS Statistics 21.  Resultados:  Vinte e cinco pacientes em dois anos, idade 72 ± 13 anos (45-92), 15 homens (60%), sepse abdominal 56% (n = 14), APACHE II 14 ± 5 (5-29) e SOFA 6 ± 3. Cultivos sem crescimento em 16 pacientes (64%), Cândida albicans 4 (16%) e não albicans em 5 (20%).  Conclusões:  A incidência de Candida albicans em pacientes que não receberam profilaxia com fluconazol é baixa, sem aumento da mortalidade, por isso consideramos que o uso de fluconazol como a gestão profilática continua a ser um medida adequada neste grupo.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Candida]]></kwd>
<kwd lng="es"><![CDATA[albicans]]></kwd>
<kwd lng="es"><![CDATA[fluconazol]]></kwd>
<kwd lng="es"><![CDATA[candidemia]]></kwd>
<kwd lng="en"><![CDATA[Candida]]></kwd>
<kwd lng="en"><![CDATA[albicans]]></kwd>
<kwd lng="en"><![CDATA[fluconazole]]></kwd>
<kwd lng="en"><![CDATA[candidemia]]></kwd>
<kwd lng="pt"><![CDATA[Candida]]></kwd>
<kwd lng="pt"><![CDATA[albicans]]></kwd>
<kwd lng="pt"><![CDATA[fluconazol]]></kwd>
<kwd lng="pt"><![CDATA[candidemia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jabeen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Farooqi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mehboob]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brandt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zfar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Agreement of direct antifungal susceptibility testing from positive blood culture bottles with the conventional method for Candida Species]]></article-title>
<source><![CDATA[J Clin Microb]]></source>
<year>2016</year>
<volume>54</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>343-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barchiesi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Orsetti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gesuita]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Skrami]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Manso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014]]></article-title>
<source><![CDATA[Infection]]></source>
<year>2015</year>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peron]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
<name>
<surname><![CDATA[Reichert-Lima]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Busso-Lopes]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Nagasako]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Lyra]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Moretti]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resistance surveillance in Candida albicans A five-year antifungal susceptibility evaluation in a Brazilian University Hospital]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2016</year>
<volume>11</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vila]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Romo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Pierce]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[McHardy]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Saville]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting Candida albicans filamentation for antifungal drug development]]></article-title>
<source><![CDATA[Virulence]]></source>
<year>2017</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>150-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallabhaneni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cleveland]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Farley]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Schaffner]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Beldavs]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008-2014]]></article-title>
<source><![CDATA[Open Forum Infect Dis]]></source>
<year>2015</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>ofv163</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohammadi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Foroughifar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Candida infections among neutropenic patients]]></article-title>
<source><![CDATA[Caspian J Intern Med]]></source>
<year>2016</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>71-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tadec]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Talarmin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gastinne]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bretonniere]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Miegeville]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Le Pape]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology, risk factor, species distribution, antifungal resistance and outcome of candidemia at a single French hospital a 7-year study]]></article-title>
<source><![CDATA[Mycoses]]></source>
<year>2016</year>
<volume>59</volume>
<page-range>296-303</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asner]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Giuleri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Diezi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marchetti]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Sanglard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acquired multidrug antifungal resistance in Candida lusitaniae during therapy]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2015</year>
<volume>59</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>7715-22</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zaidi]]></surname>
<given-names><![CDATA[KU]]></given-names>
</name>
<name>
<surname><![CDATA[Mani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thawani]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mehra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Total protein profile and drug resistance in Candida albicans isolated from clinical samples]]></article-title>
<source><![CDATA[Mol Biol Int]]></source>
<year>2016</year>
<volume>2016</volume>
<page-range>4982131</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
